

**IBC Meeting Minutes**  
4/9/2026 12:00 PM  
CMRI Conference Room 31 & Teams

**MEETING TIME RECORDS**

Meeting start time: 12:03

Meeting end time: 12:47

**VOTING MEMBER ATTENDANCE**

Name of IBC Member	Committee Role	Late Arrival Time	Early Departure Time
Daniel Heruth	Chair, Animal Expert, Lab Rep		
Todd Bradley	Co-Chair, Lab Rep		
Tarak Srivastava	Lab Rep	12:09	
Judy Dilts	Local Non-Affiliated		
Tamie Crutchfield	Occupational Health		

**VOTING MEMBERS ABSENT**

Paul Ramlow	BSO, Animal Expert, Lab Rep		
James Slaughter	Local Non-Affiliated		

**NON-VOTING MEMBERS PRESENT**

Foster St. Claire	AV & Ex-Officio		
-------------------	-----------------	--	--

**ADMINISTRATIVE STAFF**

Saskia Miller	Director of the ORI		
Lizzie Short	Associate Director of the IBC		
Daniel Crabtree	Sr. IBC Manager		
Kelleigh Pearson	Administrative Project Coordinator		

**QUORUM INFORMATION**

Number of SAFETY members on the roster: 7

**GUEST NAMES**

Scott Younger

**Conflict of Interest (COI):** Chair reminded the Committee to declare any COI.

**Previous Meeting minutes approved:** Yes

A motion to approve was made and seconded. The motion passed with 4 votes in favor and 3 absent.

## BIOSAFETY COMMITTEE UPDATES

### 1. Biological Safety Officer (BSO) Updates

- a. N/A

### 2. Office of Research Integrity (ORI) Updates

- a. The annual committee member evaluations have been completed and letters of appreciation will be sent out soon.

## REVIEW OF SUBMISSIONS

De Novo Review

### 3. Review of IBC00114

Title:	Rare Genetic Variants
Investigator:	Scott Younger
Submission ID	IBC00114
Attempt to Express Foreign Genes:	None
Protein Produced:	Proteins produced from vectors are required for 1) viral packaging, 2) genome editing (Cas9), and/or 3) fluorescent labeling (e.g. GFP)
Agents:	<ul style="list-style-type: none"> <li>• Escherichia coli K12 or derivative</li> <li>• Human immunodeficiency virus (HIV) types 2 (Retroviruses )</li> <li>• Human Derived Blood and Blood Types</li> <li>• FL-6171 (Fibroblast Lung)</li> <li>• HEK-293T</li> <li>• iPSC-dCas9-KRAB</li> <li>• Human induced pluripotent stem cells</li> <li>• Fibroblast</li> </ul>
Agent Characteristics:	Biological Agent Sources: <ul style="list-style-type: none"> <li>• ATCC</li> <li>• CMRI</li> <li>• Coriell -Fibroblast, lung, GM06171</li> <li>• Coriell</li> <li>• ThermoFisher</li> <li>• Addgene</li> <li>• Consented study participants</li> </ul>

Agent Containment:	Biological Containment Levels: <ul style="list-style-type: none"> <li>• HEK-293T: BSL-2</li> <li>• Human induced pluripotent stem cells: BSL-2</li> <li>• FL-6171 (Fibroblast Lung): BSL-2</li> <li>• iPSC-dCas9-KRAB: BSL-2</li> <li>• Human induced pluripotent stem cells: BSL-2</li> <li>• Fibroblast: BSL-2</li> <li>• Escherichia coli K12 or derivative: BSL-1</li> <li>• Human immunodeficiency virus (HIV) types 2 (Retroviruses ): BSL-2</li> <li>• Human Derived Blood and Blood Types: BSL-2</li> </ul>
Applicable NIH Guidelines:	<ul style="list-style-type: none"> <li>• Section III-D</li> <li>• Section III-D-3</li> </ul>

**Determination:** Modifications Required

**Last day of continuing review period:** 4/8/2027

**Required modifications:**

1. Dual Use Research of Concern Section
  - a. The statement that the work is “for research use only” does not, by itself, address Dual Use Research of Concern considerations. Please revise this section to clearly explain why the proposed research does not meet the criteria for dual use.
2. Exposure Assessment and Protective Equipment Section
  - a. The investigator did not describe the potential consequences of exposure to lentiviral particles. Additionally, the investigator should describe the risks and potential consequences associated with bloodborne pathogens due to the handling of blood and blood derived cell lines.
  - b. Please elaborate on the statement “may get infected with very mild symptoms” to clarify the anticipated health risks.
  - c. Add the following language to this section:  
Occupational exposures to blood and body fluids should be considered an emergent medical concern and must be reported within 15 minutes of the incident. Exposed areas should be immediately cleaned with soap and water, and mucous membranes flushed with copious amounts of water or saline. Staff must immediately report the exposure to their supervisor and the Occupational Health Nurse.
3. Risk Group and Containment Practices Section
  - a. Please provide specific information regarding the rooms located between tissue culture rooms.
4. Waste Management Section
  - a. Occupational Health information included in this section should be removed and relocated to the Exposure Assessment and Protective Equipment section.
5. Recombinant or Synthetic Nucleic Acid Work Description Section

- a. Please include additional detail regarding the genetic targets. Specify whether the work is genome wide or pathway specific, identify the targeted pathways or genes, and indicate whether the genes will be knocked out, overexpressed, or otherwise modified.

**Comments:**

The Vice-Chair introduced the Principal Investigator (PI) and invited him to begin the presentation. The PI presented his protocol to the Committee and responded to questions. Following discussion, the Committee thanked the PI, and the PI left the meeting at 12:26 p.m.

The Committee then discussed the protocol. After further deliberation, the Committee agreed on the appropriate revisions needed to secure approval.

A Member moved to require modifications to secure approval. The motion was seconded and passed.

**Supporting documents:**

None

**Votes:**

**For:** 5  
**Against:** 0  
**Recused:** 0  
**Absent:** 2  
**Abstained:** 0

**REVIEW OF OTHER AGENDA ITEMS**

**ACKNOWLEDGMENTS SECTION**

The following items were approved outside of a convened IBC meeting. The Committee reviewed and acknowledged the following items during this meeting.

<b><u>ID</u></b>	<b><u>Name</u></b>	<b><u>State</u></b>	<b><u>Specialist</u></b>	<b><u>Agenda Type</u></b>
CR202600005	Continuing Review for IBC00095	Approved	Daniel Crabtree	Admin Approval
SAMEND202600008	Amendment for IBC00074	Approved	Daniel Crabtree	Admin Approval
SAMEND202600009	Amendment for IBC00080	Approved	Daniel Crabtree	Admin Approval

<b><u>ID</u></b>	<b><u>Name</u></b>	<b><u>State</u></b>	<b><u>Specialist</u></b>	<b><u>Agenda Type</u></b>
SAMEND202600010	Amendment for IBC00074	Approved	Daniel Crabtree	Admin Approval
SAMEND202600011	Amendment for IBC00101	Approved	Daniel Crabtree	Admin Approval
SAMEND202600012	Amendment for IBC00086	Approved	Elizabeth Short	Admin Approval
SAMEND202600013	Amendment for IBC00105	Approved	Daniel Crabtree	Admin Approval
SAMENDCR202600001	Amendment/CR for IBC00086	Approved	Elizabeth Short	Admin Approval